Endo International PLC (NASDAQ:ENDP) (TSE:ENL)’s share price rose 6.4% on Monday . The stock traded as high as $9.43 and last traded at $9.28. Approximately 5,669,640 shares traded hands during mid-day trading, a decline of 5% from the average daily volume of 5,957,790 shares. The stock had previously closed at $8.72.
ENDP has been the subject of several research analyst reports. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a research note on Sunday, July 23rd. Deutsche Bank AG dropped their price objective on Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, July 7th. Mizuho reaffirmed a “buy” rating and issued a $19.00 price objective (up from $18.00) on shares of Endo International PLC in a research note on Thursday, May 25th. Vetr raised Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 price objective for the company in a research note on Wednesday, May 17th. Finally, ValuEngine downgraded Endo International PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have given a buy rating to the company. Endo International PLC currently has an average rating of “Hold” and a consensus price target of $14.49.
The firm’s market cap is $2.11 billion. The stock has a 50 day moving average of $9.16 and a 200-day moving average of $10.98.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The company had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. During the same period in the previous year, the business earned $0.86 EPS. The company’s revenue was down 4.9% on a year-over-year basis. On average, equities analysts expect that Endo International PLC will post $3.51 EPS for the current fiscal year.
In other news, COO Terrance J. Coughlin bought 20,000 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were bought at an average cost of $7.70 per share, with a total value of $154,000.00. Following the purchase, the chief operating officer now directly owns 181,369 shares in the company, valued at $1,396,541.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Paul Campanelli bought 6,500 shares of the business’s stock in a transaction on Monday, August 14th. The shares were purchased at an average cost of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the purchase, the chief executive officer now owns 213,620 shares in the company, valued at $1,647,010.20. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 36,000 shares of company stock worth $279,460. Company insiders own 0.50% of the company’s stock.
A number of large investors have recently made changes to their positions in ENDP. OppenheimerFunds Inc. raised its stake in Endo International PLC by 182.9% during the 1st quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after purchasing an additional 1,857,678 shares during the period. Bank of New York Mellon Corp raised its stake in Endo International PLC by 38.7% during the 1st quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after purchasing an additional 633,904 shares during the period. Diamond Hill Capital Management Inc. acquired a new stake in Endo International PLC during the 2nd quarter valued at $5,454,000. Ameriprise Financial Inc. raised its stake in Endo International PLC by 685.0% during the 1st quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock valued at $6,185,000 after purchasing an additional 483,545 shares during the period. Finally, American International Group Inc. raised its stake in Endo International PLC by 451.5% during the 1st quarter. American International Group Inc. now owns 396,887 shares of the company’s stock valued at $4,429,000 after purchasing an additional 324,922 shares during the period. 90.74% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This story was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.themarketsdaily.com/2017/09/13/endo-international-plc-endp-stock-price-up-6-4.html.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.